---
title: "EQT is in advanced talks to buy Qiagen for more than $50 a share"
url: "https://etf.net/news/eqt-in-talks-to-buy-qiagen-2026-10-20"
published_at: "2026-10-20T18:14:22.534Z"
updated_at: "2026-10-20T18:14:22.534Z"
byline: "ETF.net Research"
---

# EQT is in advanced talks to buy Qiagen for more than $50 a share

KKR has also bid, no sale is agreed, and the shares are still trading below $50.

By ETF.net Research. Published Oct 20, 2026.

Swedish buyout firm EQT is in advanced talks to acquire Qiagen, the Dutch diagnostics and sample-testing company listed in New York and Frankfurt, after submitting a binding offer of more than $50 a share, Bloomberg reported Tuesday, citing people familiar with the matter. KKR has also bid. No sale has been agreed.

The $50 figure is not new. Bloomberg reported on July 9 that Qiagen was already drawing interest from EQT, that KKR had expressed interest too, and that some suitors had indicated they might offer at least $50 a share if they decided to bid.

What Bloomberg added on Tuesday is that EQT's offer is binding and the talks are advanced, a step past those July indications. It described the potential acquisition as a $10 billion deal.

Qiagen's New York shares, QGEN, were at $49.17 at 2:05 p.m. in New York, up **5.6%** from Monday's close of $46.55, after trading as high as $50.82 and falling back below $50. Still under the bid, with no sale agreed and KKR still bidding, the shares are the price of a possible sale, not a finished one.

Source: etf.net, https://etf.net/news/eqt-in-talks-to-buy-qiagen-2026-10-20. Please cite the page URL.